Comment on CMS-2026-1255-0001

Summary: Pfizer Inc. supports the proposed rule to expand interoperability and electronic prior authorization standards to prescription drugs, citing benefits for patient access and administrative efficiency. The company also advocates for specific improvements, including uniform 24-hour decision timeframes, increased transparency of utilization management criteria, and the protection of prior authorizations during plan transitions.